Why Do the Patients with Hirschsprung Disease Get Redo Pull-Through Operation?
26 March 2018
04 June 2018
01 August 2018 (eFirst)
Introduction The treatment of Hirschsprung disease (HD) is pull-through (PT) surgery. Redo PT can be performed in 1 to 10% of patients after initial PT. In this study, we reviewed the causes and associated factors of redo PT.
Materials and Methods We retrospectively reviewed medical charts of 657 patients with HD who underwent surgeries between September 1979 and January 2016. The indications for redo PT are as follows. First, there were persistent obstructive symptoms after the first operation, (1) with transition zone shown definitely on contrast study, (2) with anatomic problems, and (3) obstructive symptoms persist despite conservative or nonredo surgical treatment without (1) and (2). We analyzed the causes and associated factors of redo PT.
Results A total of 49 (7.5%) patients underwent redo PT. Among them, 41 and 8 patients underwent PT twice and three times, respectively. Among 57 cases of redo, the causes of redo included pathologic problem (n = 28)—aganglionosis (n = 20), hypoganglionosis (n = 4), immature ganglion cell (n = 4)—or anatomic problem (n = 21)—stricture (n = 13), fistula and/or abscess (n = 8) at anastomosis. Comparing associated factors between the nonredo and redo groups, the redo group had longer initial PT operation time (p = 0.001), more postoperative complications (p < 0.001), and more transanal endorectal PT (TERPT) approach as initial PTs (p < 0.001). According to causes of redo, the anatomic problem group underwent more third PTs than the pathologic problem group (p = 0.010).
Conclusion Approximately 7.5% of patients experienced redo PT. The cause of redo included pathologic (n = 28) or anatomic problem (n = 21). Longer operation time, more complications, and TERPT were associated with redo. The anatomic problem group underwent more third PTs than the pathologic problem group.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
- 1 Cogbill TH, Lilly JR. Acquired aganglionosis after Soave's procedure for Hirschsprung's disease. Arch Surg 1982; 117 (10) 1346-1347
- 2 Lawal TA, Chatoorgoon K, Collins MH, Coe A, Peña A, Levitt MA. Redo pull-through in Hirschsprung's [corrected] disease for obstructive symptoms due to residual aganglionosis and transition zone bowel. J Pediatr Surg 2011; 46 (02) 342-347
- 3 Ralls MW, Coran AG, Teitelbaum DH. Reoperative surgery for Hirschsprung disease. Semin Pediatr Surg 2012; 21 (04) 354-363
- 4 Shayan K, Smith C, Langer JC. Reliability of intraoperative frozen sections in the management of Hirschsprung's disease. J Pediatr Surg 2004; 39 (09) 1345-1348
- 5 Dasgupta R, Langer JC. Evaluation and management of persistent problems after surgery for Hirschsprung disease in a child. J Pediatr Gastroenterol Nutr 2008; 46 (01) 13-19
- 6 Schweizer P, Berger S, Schweizer M, Holschneider AM, Beck O. Repeated pull-through surgery for complicated Hirschsprung's disease--principles derived from clinical experience. J Pediatr Surg 2007; 42 (03) 536-543
- 7 Kapur RP. Histology of the transition zone in Hirschsprung disease. Am J Surg Pathol 2016; 40 (12) 1637-1646
- 8 Dasgupta R, Langer JC. Transanal pull-through for Hirschsprung disease. Semin Pediatr Surg 2005; 14 (01) 64-71
- 9 Pini-Prato A, Mattioli G, Giunta C. , et al. Redo surgery in Hirschsprung disease: what did we learn? Unicentric experience on 70 patients. J Pediatr Surg 2010; 45 (04) 747-754
- 10 Dingemans A, van der Steeg H, Rassouli-Kirchmeier R, Linssen MW, van Rooij I, de Blaauw I. Redo pull-through surgery in Hirschsprung's disease: short-term clinical outcome. J Pediatr Surg 2017; 52 (09) 1446-1450
- 11 Ehrenpreis T. Acquired megacolon as a complication of recto-sigmoidectomy for Hirschsprung's disease. Arch Dis Child 1965; 40: 180-182
- 12 Bag MJ, Sáez T, Varas J. , et al. Surgical acquired aganglionosis: myth or reality?. Pediatr Surg Int 2014; 30 (08) 797-802
- 13 Bischoff A, Levitt MA, Peña A. Total colonic aganglionosis: a surgical challenge. How to avoid complications?. Pediatr Surg Int 2011; 27 (10) 1047-1052
- 14 Cohen MC, Moore SW, Neveling U, Kaschula RO. Acquired aganglionosis following surgery for Hirschsprung's disease: a report of five cases during a 33-year experience with pull-through procedures. Histopathology 1993; 22 (02) 163-168
- 15 Inoue K, Shimotake T, Tomiyama H, Iwai N. Mutational analysis of the RET and GDNF gene in children with hypoganglionosis. Eur J Pediatr Surg 2001; 11 (02) 120-123
- 16 Friedmacher F, Puri P. Classification and diagnostic criteria of variants of Hirschsprung's disease. Pediatr Surg Int 2013; 29 (09) 855-872
- 17 Yang H-B, Kim H-Y, Kim S-H. , et al. Prevalence and significance of immature ganglion cell in Hirschsprung's disease. J Korean Assoc Pediatr Surg 2013; 18 (02) 122-129
- 18 Seo S, Miyake H, Hock A. , et al. Duhamel and transanal endorectal pull-throughs for Hirschsprung' disease: a systematic review and meta-analysis. Eur J Pediatr Surg 2018; 28 (01) 81-88
- 19 van de Ven TJ, Sloots CE, Wijnen MH. , et al. Transanal endorectal pull-through for classic segment Hirschsprung's disease: with or without laparoscopic mobilization of the rectosigmoid?. J Pediatr Surg 2013; 48 (09) 1914-1918
- 20 De La Torre L, Langer JC. Transanal endorectal pull-through for Hirschsprung disease: technique, controversies, pearls, pitfalls, and an organized approach to the management of postoperative obstructive symptoms. Semin Pediatr Surg 2010; 19 (02) 96-106
- 21 Sun S, Chen G, Zheng S, Dong K, Xiao X. Usefulness of posterior sagittal anorectoplasty for redo pull-through in complicated and recurrent Hirschsprung disease: experience with a single surgical group. J Pediatr Surg 2017; 52 (03) 458-462
- 22 Ralls MW, Coran AG, Teitelbaum DH. Redo pull-through for Hirschsprung disease. Pediatr Surg Int 2017; 33 (04) 455-460